Professor Junia V. Melo

Publications


Journals

  • Carella AM; Goldman JM; Martinelli G; Melo JV; Perrotti D. (1 Dec 2011). Chronic myeloid leukemia: the basis of treatment for tomorrow. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 96:1737-U24. Author weblink DOI.
  • Schultheis B; Nijmeijer BA; Yin H; Gosden RG; Melo JV. (Mar 2012). Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res. 36:271-274. DOI.
  • Diamond JM; Melo JV. (1 Feb 2011). Mechanisms of resistance to BCR--ABL kinase inhibitors. LEUKEMIA & LYMPHOMA. 52:12-22. DOI.
  • Sears D; Luong P; Yuan M; Nteliopoulos G; Man YKS; Melo JV; Basu S. (1 Nov 2010). Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia. CELL DEATH & DISEASE. 1. DOI.
  • Score J; Calasanz MJ; Ottman O; Pane F; Yeh RF; Sobrinho-Simoes MA; Kreil S; Ward D; et alHidalgo-Curtis C; Melo JV; Wiemels J; Nadel B; Cross NCP; Grand FH. (1 Oct 2010). Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. LEUKEMIA. 24:1742-1750. Author weblink DOI.
  • Sobrinho-Simões M; Wilczek V; Score J; Cross NC; Apperley JF; Melo JV. (26 Aug 2010). In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood. 116:1329-1335. DOI.
  • Klawitter J; Kominsky DJ; Brown JL; Klawitter J; Christians U; Leibfritz D; Melo JV; Eckhardt SG; et alSerkova NJ. (1 Sep 2009). Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. BRITISH JOURNAL OF PHARMACOLOGY. 158:588-600. Author weblink DOI.
  • Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ. (15 May 2009). Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL-Positive Cells. CLINICAL CANCER RESEARCH. 15:3442-3450. Author weblink DOI.
  • Crawford LJ; Windrum P; Magill L; Melo JV; McCallum L; McMullin MF; Ovaa H; Walker B; et alIrvine AE. (1 Mar 2009). Proteasome proteolytic profile is linked to Bcr-Abl expression. EXPERIMENTAL HEMATOLOGY. 37:357-366. Author weblink DOI.
  • Batlle A; Papadopoulou V; Gomes AR; Willimott S; Melo JV; Naresh K; Lam EW; Wagner SD. (May 2009). CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression. Mol Immunol. 46:1727-1735. DOI.
  • Chase A; Schultheis B; Kreil S; Baxter J; Hidalgo-Curtis C; Jones A; Zhang L; Grand FH; et alMelo JV; Cross NCP. (1 Feb 2009). Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1. LEUKEMIA. 23:358-364. Author weblink DOI.
  • Mohty M; Szydlo RM; Yong ASM; Apperley JF; Goldman JM; Melo JV. (1 Sep 2008). Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. BLOOD. 112:2163-2166. Author weblink DOI.
  • Goldman JM; Melo JV. (1 Jan 2008). BCR-ABL in chronic myelogenous leukemia - How does it work?. ACTA HAEMATOLOGICA. 119:212-217. Author weblink DOI.
  • Bonhoure E; Lauret A; Barnes DJ; Martin C; Malavaud B; Kohama T; Melo JV; Cuvillier O. (1 May 2008). Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. LEUKEMIA. 22:971-979. Author weblink DOI.
  • Brazma D; Grace C; Howard J; Melo JV; Holyoke T; Apperley JF; Nacheva EP. (Nov 2007). Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes Cancer. 46:1039-1050. DOI.
  • Raguz S; Randle RA; Sharpe ER; Foekens JA; Sieuwerts AM; Meijer-van Gelder ME; Melo JV; Higgins CF; et alYagüe E. (1 Mar 2008). Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer. Int J Cancer. 122:1058-1067. DOI.
  • Strathdee G; Holyoake TL; Sim A; Parker A; Oscier DG; Melo JV; Meyer S; Eden T; et alDickinson AM; Mountford JC; Jorgensen HG; Soutar R; Brown R. (1 Sep 2007). Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. CLINICAL CANCER RESEARCH. 13:5048-5055. Author weblink DOI.
  • Mughal T; Cortes J; Cross NCP; Donato N; Hantschel O; Jabbour E; Kantarjian H; Melo JV; et alSkorski T; Silver RT; Goldman JM. (1 Jul 2007). Chronic myeloid leukemia - some topical issues. LEUKEMIA. 21:1347-1352. Author weblink DOI.
  • Griffiths SD; Burthem J; Unwin RD; Holyoake TL; Melo JV; Lucas GS; Whetton AD. (1 Jun 2007). The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. MOLECULAR BIOTECHNOLOGY. 36:81-89. Author weblink DOI.
  • Konig H; Haertel N; Schultheis B; Schatz M; Lorentz C; Melo JV; Hehlmann R; Hochhaus A; et alLa Rosee P. (1 Jun 2007). Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 92:838-841. Author weblink DOI.
  • Melo JV. (1 Jun 2003). Resistance to imatinib mesylate in CML: all BCR-ABL mutations "are created equal but some are more equal than others". Blood. 11, 101:4231. Author weblink.
  • Moller GMO; Frost V; Melo JV; Chantry A. (3 Apr 2007). Upregulation of the TGF beta signalling pathway by Bcr-Abl: Implications for haemopoietic cell growth and chronic myeloid leukaemia. FEBS LETTERS. 581:1329-1334. Author weblink DOI.
  • Melo JV; Barnes DJ. (Jun 2007). Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 7:441-453. DOI.
  • Mohty M; Yong AS; Szydlo RM; Apperley JF; Melo JV. (1 Jul 2007). The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood. 110:380-383. DOI.
  • Lerma EI; Nguyen VA; Wang T; Tipping A; Melo JV; Kufe D; Austin DJ; Deisseroth A. (Feb 2007). Novel compounds with antiproliferative activity against imatinib-resistant cell lines. Mol Cancer Ther. 6:655-666. DOI.
  • Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV. (Mar 2007). Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines. Leukemia. 21:421-426. DOI.
  • Pocaly M; Lagarde V; Etienne G; Ribeil J-A; Claverol S; Bonneu M; Moreau-Gaudry F; Guyonnet-Duperat V; et alHermine O; Melo JV; Dupouy M; Turcq B; Mahon F-X; Pasquet J-M. (1 Jan 2007). Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. LEUKEMIA. 21:93-101. Author weblink DOI.
  • Barnes DJ; Melo JV. (Dec 2006). Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle. 5:2862-2866.
  • La Rosee P; Jia T; Demehri S; Haertel N; de Vries P; Bonham L; Hollenback D; Singer JW; et alMelo JV; Druker BJ; Deininger MW. (1 Nov 2006). Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. CLINICAL CANCER RESEARCH. 12:6540-6546. Author weblink DOI.
  • Ono A; Kono K; Ikebe D; Muto A; Sun J; Kobayashi M; Ueda K; Melo JV; et alIgarashi K; Tashiro S. (1 Jan 2007). Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells. GENES CHROMOSOMES & CANCER. 46:67-74. Author weblink DOI.
  • Yoshida C; Yoshida F; Sears DE; Hart SM; Ikebe D; Muto A; Basu S; Igarashi K; et alMelo JV. (1 Feb 2007). Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1. Blood. 109:1211-1219. DOI.
  • Melo JV; Chuah C. (8 May 2007). Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 249:121-132. DOI.
  • Melo JV. (15 Aug 2006). Imatinib and ABCG2: who controls whom?. BLOOD. 108:1116-1117. Author weblink DOI.
  • Hamilton A; Elrick L; Myssina S; Copland M; Jorgensen H; Melo JV; Holyoake T. (1 Jun 2006). BCR-ABL activity and its response to drugs can be determined in CD34(+) CML stem cells by CrkL phosphorylation status using flow cytometry. LEUKEMIA. 20:1035-1039. Author weblink DOI.
  • Pabst T; Stillner E; Neuberg D; Nimer S; Willman CL; List AF; Melo JV; Tenen DG; et alMueller BU. (1 May 2006). Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY. 133:400-402. Author weblink DOI.
  • Zhang LY; Smith ML; Schultheis B; Fitzgibbon J; Lister TA; Melo JV; Cross NC; Cavenagh JD. (Apr 2006). A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res. 30:373-378. DOI.
  • Khorashad JS; Anand M; Marin D; Saunders S; Al-Jabary T; Iqbal A; Margerison S; Melo JV; et alGoldman JM; Apperley JF; Kaeda J. (Apr 2006). The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia. 20:658-663. DOI.
  • Yong AS; Szydlo RM; Goldman JM; Apperley JF; Melo JV. (1 Jan 2006). Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood. 107:205-212. DOI.
  • Chuah C; Barnes DJ; Kwok M; Corbin A; Deininger MW; Druker BJ; Melo JV. (Nov 2005). Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia. 19:1896-1904. DOI.
  • Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; et alMelo JV. (1 Oct 2005). Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 65:8912-8919. DOI.
  • Barnes DJ; Schultheis B; Adedeji S; Melo JV. (22 Sep 2005). Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene. 24:6432-6440. DOI.
  • Radujkovic A; Schad M; Topaly J; Veldwijk MR; Laufs S; Schultheis BS; Jauch A; Melo JV; et alFruehauf S; Zeller WJ. (Jul 2005). Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG. Leukemia. 19:1198-1206. DOI.
  • Schultheis B; Szydlo R; Mahon FX; Apperley JF; Melo JV. (15 Jun 2005). Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood. 105:4893-4894. DOI.
  • Sánchez-Arévalo Lobo VJ; Aceves Luquero CI; Alvarez-Vallina L; Tipping AJ; Viniegra JG; Hernández Losa J; Parada Cobo C; Galán Moya EM; et alGayoso Cruz J; Melo JV; Ramón y Cajal S; Sánchez-Prieto R. (1 Apr 2005). Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J. 387:231-238. DOI.
  • Cwynarski K; Melo JV; Dazzi F. (1 Mar 2005). Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia? Reply. LEUKEMIA. 19:457-457. Author weblink DOI.
  • Desplat V; Belloc F; Lagarde V; Boyer C; Melo JV; Reiffers J; Praloran V; Mahon FX. (1 Jan 2005). Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines. Cancer. 103:102-110. DOI.
  • Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; et alMelo JV. (Aug 2004). Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia. 18:1352-1356. DOI.
  • Cwynarski K; Laylor R; Macchiarulo E; Goldman J; Lombardi G; Melo JV; Dazzi F. (Aug 2004). Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 18:1332-1339. DOI.
  • Melo JV; Deininger MWN. (1 Jun 2004). Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA. 18:545-+. Author weblink DOI.
  • Yoshida C; Melo JV. (Jun 2004). Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol. 79:420-433.
  • Tipping AJ; Melo JV. (Mar 2004). Comparative gene expression profile of p185(Bcr-Abl) versus p210(Bcr-Abl) expressing cells. Leuk Res. 28:219-220.
  • La Rosée P; Johnson K; Corbin AS; Stoffregen EP; Moseson EM; Willis S; Mauro MM; Melo JV; et alDeininger MW; Druker BJ. (1 Jan 2004). In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood. 103:208-215. DOI.
  • Melo J; Barnes DJ. (2004). Switching off oncogenic signals in chronic myeloid leukaemia. Hematol J. 5 Suppl 3:S183-S187. DOI.
  • Tipping AJ; Deininger MW; Goldman JM; Melo JV. (Nov 2003). Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol. 31:1073-1080.
  • Goldman JM; Melo JV. (9 Oct 2003). Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med. 349:1451-1464. DOI.
  • Goldman JM; Melo JV. (9 Oct 2003). Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment. NEW ENGLAND JOURNAL OF MEDICINE. 349:1451-1464. Author weblink DOI.
  • Schultheis B; Wang L; Clark RE; Melo JV. (Oct 2003). BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis. Leukemia. 17:2054-2055. DOI.
  • Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST. (15 Sep 2003). Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res. 63:5716-5722.
  • Melo JV; Tipping AJ. (15 Sep 2003). Location matters... BLOOD. 102:1941-1942. Author weblink.
  • Kaeda J; Apperley J; Melo J; Cross N; Goldman J. (15 Jun 2003). Monitoring CML after nonmyeloablative transplantations: how negative is negative?. Blood. 101:5084. DOI.
  • Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S. (May 2003). Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL. Br J Haematol. 121:672-673.
  • Dong R; Cwynarski K; Entwistle A; Marelli-Berg F; Dazzi F; Simpson E; Goldman JM; Melo JV; et alLechler RI; Bellantuono I; Ridley A; Lombardi G. (1 May 2003). Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood. 101:3560-3567. DOI.
  • Tipping AJ; Melo JV. (Apr 2003). Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies. Semin Hematol. 40:83-91. DOI.
  • Mahon FX; Belloc F; Lagarde V; Chollet C; Moreau-Gaudry F; Reiffers J; Goldman JM; Melo JV. (15 Mar 2003). MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 101:2368-2373. DOI.
  • Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; et alStauss HJ. (1 Feb 2003). Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood. 101:1007-1014. DOI.
  • Melo JV; Hughes TP; Apperley JF. (2003). Chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program. 132-152.
  • Barnes DJ; Melo JV. (Jan 2003). Management of chronic myeloid leukemia: targets for molecular therapy. Semin Hematol. 40:34-49. DOI.
  • Tipping AJ; Mahon FX; Zafirides G; Lagarde V; Goldman JM; Melo JV. (Dec 2002). Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia. 16:2349-2357. DOI.
  • Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS. (Dec 2002). Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res. 1:89-95.
  • Barthe C; Gharbi MJ; Lagarde V; Chollet C; Cony-Makhoul P; Reiffers J; Goldman JM; Melo JV; et alMahon FX. (Oct 2002). Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br J Haematol. 119:109-111.
  • Luzzatto L; Frassoni F; Melo JV. (Sep 2002). Imatinib: can one outwit chronic myeloid leukemia?. Haematologica. 87:898-901.
  • Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; et alColombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM. (15 Aug 2002). Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 347:481-487. DOI.
  • Luzzatto L; Melo JV. (1 Aug 2002). Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells. Blood. 100:1105.
  • Hoover RR; Mahon FX; Melo JV; Daley GQ. (1 Aug 2002). Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 100:1068-1071.
  • Tabrizi R; Mahon FX; Cony Makhoul P; Lagarde V; Lacombe F; Berthaud P; Melo JV; Reiffers J; et alBelloc F. (Jun 2002). Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571. Leukemia. 16:1154-1159. DOI.
  • O'Brien SG; Vieira SA; Connors S; Bown N; Chang J; Capdeville R; Melo JV. (1 May 2002). Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood. 99:3465-3467.
  • Schultheis B; Carapeti-Marootian M; Hochhaus A; Weisser A; Goldman JM; Melo JV. (1 Mar 2002). Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood. 99:1766-1775.
  • Sauce D; Bodinier M; Garin M; Petracca B; Tonnelier N; Duperrier A; Melo JV; Apperley JF; et alFerrand C; Hervé P; Lang F; Tiberghien P; Robinet E. (15 Feb 2002). Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood. 99:1165-1173.
  • Barnes DJ; Melo JV. (2002). Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol. 108:180-202.
  • Tipping AJ; Mahon FX; Lagarde V; Goldman JM; Melo JV. (15 Dec 2001). Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood. 98:3864-3867.
  • Demiroglu A; Steer EJ; Heath C; Taylor K; Bentley M; Allen SL; Koduru P; Brody JP; et alHawson G; Rodwell R; Doody ML; Carnicero F; Reiter A; Goldman JM; Melo JV; Cross NC. (15 Dec 2001). The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 98:3778-3783.
  • Vieira SA; Deininger MW; Sorour A; Sinclair P; Foroni L; Goldman JM; Melo JV. (Dec 2001). Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene. Genes Chromosomes Cancer. 32:353-363.
  • Raghavan M; Abboudi Z; Cross NCP; Steer J; Schultheis B; Melo JV. (16 Nov 2001). A novel t(5;10) (q35;q24) translocation in chronic myelomonocytic leukemia that is not associated with H4/PDGF beta R fusion. BLOOD. 98:193B-193B. Author weblink.
  • de la Fuente J; Merx K; Steer J; Muller M; Szydlo RM; Maywald O; Berger U; Hehlmann R; et alChase A; Goldman JM; Cross NCP; Melo JV; Hochhaus A. (16 Nov 2001). ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. BLOOD. 98:351A-351A. Author weblink.
  • Tipping AJ; Deininger MW; Goldman JM; Melo JV. (16 Nov 2001). Comparative microarray expression analysis of STI571-sensitive and resistant subtypes of a CML cell line. BLOOD. 98:306A-306A. Author weblink.
  • Barnes DJ; Goldman JM; Melo JV. (16 Nov 2001). Dose dependent effects of BCR-ABL on the phenotype of murine haematopoietic cells. BLOOD. 98:145A-145A. Author weblink.
  • Etienne G; Lagarde V; Reiffers J; Melo JV; Mahon FX. (16 Nov 2001). Effects of the tyrosine kinase inhibitor PP1 on STI571-resistant BCR-ABL positive cell lines. BLOOD. 98:617A-617A. Author weblink.
  • Elliston DJ; Garrett E; Melo JV; Apperley JF. (16 Nov 2001). Efficient marking of CML perpheral blood CD34+cells and their subsets, using two different packaging line systems. BLOOD. 98:403B-403B. Author weblink.
  • Sauce D; Garin MI; Bodinier M; Duperrier A; Melo JV; Apperley JF; Ferrand C; Herve P; et alLang F; Cahn JY; Tiberghien P; Robinet E. (16 Nov 2001). Neomycine phosphotransferase/G418-based selection, to the difference of membrane marker (Delta LNGFR)-based selection, impairs the anti-EBV potential of retrovirally-transduced human gene-modified T cells. BLOOD. 98:406B-406B. Author weblink.
  • Hoover RR; Mahon FX; Melo JV; Daley GQ. (16 Nov 2001). Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. BLOOD. 98:617A-617A. Author weblink.
  • Schultheis B; Carapeti-Marootian M; Goldman JM; Melo JV. (16 Nov 2001). Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: Possible inadequacy of a negative feedback mechanism. BLOOD. 98:144A-145A. Author weblink.
  • Desplat V; Belloc F; Lagarde V; Melo JV; Reiffers J; Mahon FX. (16 Nov 2001). Overproduction of BCR-ABL induces apoptosis in STI571-resistant BaF/BCR-ABL cell lines. BLOOD. 98:148A-148A. Author weblink.
  • Pourgourides E; Heath C; Melo JV; Rahemtulla A; Cross NCP. (16 Nov 2001). Specific action of FGFR inhibitors against t(4;14) positive myeloma cells. BLOOD. 98:370A-371A. Author weblink.
  • Cwynarski K; Laylor R; Melo JV; Dazzi F. (16 Nov 2001). STI571 inhibits the activaiton and proliferation of normal T lymphocytes. BLOOD. 98:256B-257B. Author weblink.
  • Vieira SAD; Deininger MWN; Goldman JM; Melo JV. (16 Nov 2001). The BCL-6 gene is transcriptionally regulated by the BCR-ABL oncogene. BLOOD. 98:302A-303A. Author weblink.
  • Schultheis B; Yong ASM; Goldman JM; Melo JV. (16 Nov 2001). The combined use of STI571 and leptomycin-B (LMB) for in vitro purging of leukemic cells in autografts for CML. BLOOD. 98:618A-618A. Author weblink.
  • Steer EJ; Demiroglu A; Heath C; Pourgourides E; Taylor K; Bentley M; Allen SL; Koduru P; et alBrody JP; Hawson G; Rodwell R; Doody ML; Carnicero F; Reiter A; Goldman JM; Melo JV; Cross NCP. (16 Nov 2001). The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: Transforming activity and specific inhibition of FGFR1 fusion proteins. BLOOD. 98:468A-468A. Author weblink.
  • de la Fuente J; Merx K; Steer EJ; Müller M; Szydlo RM; Maywald O; Berger U; Hehlmann R; et alGoldman JM; Cross NC; Melo JV; Hochhaus A; German CML Study Group. (1 Nov 2001). ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood. 98:2879-2880.
  • Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; et alGoldman JM; Melo JV. (1 Nov 2001). Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res. 61:8005-8013.
  • Carella AM; Melo JV; Goldman JM. (Oct 2001). Portofino International Conference on Chronic Myeloid Leukemia. Exp Hematol. 29:1147-1156.
  • Barthe C; Cony-Makhoul P; Melo JV; Reiffers J; Mahon FX. (21 Sep 2001). Roots of clinical resistance to STI-571 cancer therapy. SCIENCE. 293:U1-U1. Author weblink.
  • Barthe C; Cony-Makhoul P; Melo JV; Mahon JR. (21 Sep 2001). Roots of clinical resistance to STI-571 cancer therapy. Science. 293:2163. DOI.
  • Melo JV; Kumberova A; van Dijk AG; Goldman JM; Yuille MR. (Sep 2001). Investigation on the role of the ATM gene in chronic myeloid leukaemia. Leukemia. 15:1448-1450.
  • Chalmers D; Ferrand C; Apperley JF; Melo JV; Ebeling S; Newton I; Duperrier A; Hagenbeek A; et alGarrett E; Tiberghien P; Garin M. (Aug 2001). Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol Ther. 4:146-148. DOI.
  • Rivas C; Miller AR; Collado M; Lam EW; Apperley JF; Melo JV. (May 2001). BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir. Mol Ther. 3:642-652. DOI.
  • Goldman JM; Melo JV. (5 Apr 2001). Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:1084-1086. DOI.
  • Melo J. (Feb 2001). Inviting leukemic cells to waltz with the devil. Nat Med. 7:156-157. DOI.
  • Garin MI; Garrett E; Tiberghien P; Apperley JF; Chalmers D; Melo JV; Ferrand C. (1 Jan 2001). Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood. 97:122-129.
  • Duke V; Kapoor A; Gricks C; Melo J; Foroni L. (Dec 2000). BCL10 deletions in haematological malignancies: a cloning artefact?. Br J Haematol. 111:1106-1108.
  • Peters DG; Hoover RR; Koh EY; Zhane HY; Mahon FX; Melo JV; Kirschmeier P; Bishop WR; et alDaley GQ. (16 Nov 2000). Activity of the farnesyl transferase inhibitor SCH66336 against BCR-ABL-induced murine leukemia, STI571-resistant CML cell lines, and primary cells from CML patients. BLOOD. 96:510A-510A. Author weblink.
  • Vieira SDA; Deininger MWN; Sorour A; Sinclair P; Foroni L; Goldman JM; Melo JV. (16 Nov 2000). Cloning of Bach2, a new transcription factor involved in the pathogenesis of chronic myeloid leukemia (CML). BLOOD. 96:458A-458A. Author weblink.
  • Mahon FX; Belloc F; Cholet C; Cony-Makhoul P; Guilhot F; Melo JV; Berthaud P; Reiffers J. (16 Nov 2000). Detection of resistance to STI571 in patients with BCR-ABL positive acute leukemia and chronic myeloid leukemia (CML) blast crisis. BLOOD. 96:471A-471A. Author weblink.
  • Garin MI; Garrett E; Tiberghien P; Apperley JF; Chalmers D; Melo JV; Ferrand C. (16 Nov 2000). In vivo expression of Herpes simplex virus thymidine kinase gene in human T-lymphocytes transduced with retroviral vectors. BLOOD. 96:802A-802A. Author weblink.
  • Schultheis B; Carapeti M; Hochhaus A; Weisser A; Zaiac M; Goldman JM; Melo JV. (16 Nov 2000). Overexpression of SOCS-2 in the advanced phase of chronic myeloid leukemia (CML). BLOOD. 96:509A-509A. Author weblink.
  • Tipping AJ; Zafirides G; Mahon FX; Goldman JM; Melo JV. (16 Nov 2000). Response of STI571-resistant cells to other chemotherapeutic drugs and signal transduction inhibitors. BLOOD. 96:98A-98A. Author weblink.
  • Mahon FX; Belloc F; Lagarde V; Reiffers J; Goldman JM; Melo JV. (16 Nov 2000). The MDR1-positive K562/DOX cell line is resistant to the ABL tyrosine kinase inhibitor STI571. BLOOD. 96:98A-98A. Author weblink.
  • Deininger MW; Goldman JM; Melo JV. (15 Nov 2000). The molecular biology of chronic myeloid leukemia. Blood. 96:3343-3356.
  • Mahon FX; Deininger MW; Schultheis B; Chabrol J; Reiffers J; Goldman JM; Melo JV. (1 Aug 2000). Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 96:1070-1079.
  • Rivas C; Chandler P; Melo JV; Simpson E; Apperley JF. (Jun 2000). Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma. Cancer Gene Ther. 7:954-962. DOI.
  • Deininger MW; Vieira S; Mendiola R; Schultheis B; Goldman JM; Melo JV. (1 Apr 2000). BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. 60:2049-2055.
  • Garin MI; Apperley JF; Melo JV. (Feb 2000). Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrow and mobilised peripheral blood. Eur J Haematol. 64:85-92.
  • Garrett E; Miller AR; Goldman JM; Apperley JF; Melo JV. (5 Jan 2000). Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line. Virology. 266:170-179. DOI.
  • Kantarjian H; Melo JV; Tura S; Giralt S; Talpaz M. (2000). Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. Hematology Am Soc Hematol Educ Program. :90-109.
  • Deininger MWN; Vieira SD; Goldman JM; Niederwieser D; Melo JV. (15 Nov 1999). A role for the oncostatin M receptor in the pathogenesis of CML?. BLOOD. 94:100A-100A. Author weblink.
  • Kapoor A; Duke V; Gricks C; Melo JV; Foroni L. (15 Nov 1999). BCL10 mutational analysis: A cloning artefact?. BLOOD. 94:60A-60A. Author weblink.
  • Miller ARM; Rivas C; Chandler P; Simpson E; Melo JV; Apperley JF. (15 Nov 1999). Development of an immune response to the truncated low affinity nerve growth factor receptor in mice. BLOOD. 94:414B-414B. Author weblink.
  • Garrett E; Staal FJ; Goldman JM; Melo JV; Apperley JF. (15 Nov 1999). Efficient cell surface marking of CML CD34(+) cells using two different forms of the Delta LNGFR gene. BLOOD. 94:410B-410B. Author weblink.
  • Rivas C; Miller ARM; Collado M; Lam EWF; Apperley JF; Melo JV. (15 Nov 1999). Induction of apoptosis using the HSV-tk/ganciclovir system in BCR-ABL expressing cells. BLOOD. 94:104A-104A. Author weblink.
  • Mahon FX; Deininger MWN; Schultheis B; Goldman JM; Melo JV. (15 Nov 1999). Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the signal transduction inhibitor STI571: Mechanisms of resistance. BLOOD. 94:656A-656A. Author weblink.
  • Garrett E; Garin MI; Miller AR; Goldman JM; Melo JV; Apperley JF. (Nov 1999). Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH-296. Br J Haematol. 107:401-408.
  • Bose S; Goldman JM; Melo JV. (Nov 1999). Mutations of the BCL10 gene are not associated with the blast crisis of chronic myeloid leukaemia. Leukemia. 13:1894-1896.
  • Spencer A; Szydlo R; Grand FH; Goldman JM; Melo JV. (Jan 1999). Abnormal patterns of immunoglobulin heavy chain gene DNA fingerprinting during chronic phase chronic myeloid leukemia. Leuk Lymphoma. 32:299-307. DOI.
  • Gora-Tybor J; Deininger MW; Goldman JM; Melo JV. (Dec 1998). The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL. Br J Haematol. 103:716-720.
  • Deininger MWN; Goldman JM; Peters G; Melo JV. (15 Nov 1998). BCR-ABL causes over-expression of Cyclin D2 in B-lymphoblasts. BLOOD. 92:216A-217A. Author weblink.
  • Garrett E; Miller ARM; Chong H; Vile RG; Goldman JM; Apperley JF; Melo JV. (15 Nov 1998). Characterisation of a replication competent retrovirus present in a GP+envAM12-derived producer cell line. BLOOD. 92:470A-470A. Author weblink.
  • Garin MI; Miller ARM; Goldman JM; Melo JV; Apperley JF. (15 Nov 1998). Characterization of retroviral-mediated gene transfer of HSV-TK and low affinity nerve growth factor receptor (LNGFR) in human T-cell lines. BLOOD. 92:377B-377B. Author weblink.
  • Garrett E; Miller ARM; Goldman JM; Melo JV; Apperley JF. (15 Nov 1998). Enhanced gene transfer into CML and normal bone marrow, and CML and mobilised peripheral blood CD34+ cells, using the recombinant fibronectin fragment CH-296. BLOOD. 92:377B-377B. Author weblink.
  • Bose S; Deininger M; Gora-Tybor J; Goldman JM; Melo JV. (1 Nov 1998). The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 92:3362-3367.
  • Deininger MWN; Goldman JM; Melo JV. (1 Jul 1998). Identification of BCR-ABL target genes using a differential display approach. BRITISH JOURNAL OF HAEMATOLOGY. 102:155-155. Author weblink.
  • Deininger MW; Bose S; Gora-Tybor J; Yan XH; Goldman JM; Melo JV. (1 Feb 1998). Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res. 58:421-425.
  • Melo JV; Bose S; GoraTybor J; Deininger M; Goldman JM. (15 Nov 1997). Detection of leukemia-associated fusion genes in leukocytes from normal people and hematopoietic cell lines using an 'improved' RT/PCR assay. BLOOD. 90:2233-2233. Author weblink.
  • Deininger WN; Bose S; GoraTybor J; Yan XH; Goldman JM; Melo JV. (15 Nov 1997). Selective induction of leukemia-associated fusion genes by high dose ionizing radiation. BLOOD. 90:1426-1426. Author weblink.
  • Deininger M; Goldman JM; Melo JV. (15 Nov 1997). The induction of apoptosis in CML cells exposed to the tyrosine kinase inhibitor CGP57148B is associated with altered gene transcription. BLOOD. 90:360-360. Author weblink.
  • GoraTybor J; Deininger M; Goldman JM; Melo JV. (15 Nov 1997). The susceptibility of CML cells to FAS (CD95) mediated apoptosis is independent of the activity of the BCR-ABL tyrosine kinase. BLOOD. 90:358-358. Author weblink.
  • Deininger MW; Goldman JM; Lydon N; Melo JV. (1 Nov 1997). The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 90:3691-3698.
  • Goldman JM; Deininger M; Melo JV. (1 Aug 1997). BCR-ABL targeted therapy in chronic myeloid leukemia (CML). EXPERIMENTAL HEMATOLOGY. 25:515-515. Author weblink.
  • Hochhaus A; Yan XH; Willer A; Hehlmann R; Gordon MY; Goldman JM; Melo JV. (Jul 1997). Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia. Leukemia. 11:933-939.
  • Melo JV. (Jun 1997). BCR-ABL gene variants. Baillieres Clin Haematol. 10:203-222.
  • Spencer A; Vulliamy T; Kaeda J; Goldman JM; Melo JV. (Feb 1997). Clonal instability preceding lymphoid blastic transformation of chronic myeloid leukemia. Leukemia. 11:195-201.
  • Garin MI; Apperley J; Melo JV. (15 Nov 1996). Ex vivo expansion of human hemopoietic cells from normal bone marrow and peripheral blood from CML patients. BLOOD. 88:2419-2419. Author weblink.
  • Hochhaus A; Cross NCP; Hehlmann R; Goldman JM; Melo JV. (15 Nov 1996). Intronic sequences of the ABL gene are frequently spliced into BCR-ABL, ABL-BCR, and ABL transcripts from patients with CML and in ABL transcripts from normal individuals. BLOOD. 88:2288-2288. Author weblink.
  • Melo JV. (1 Oct 1996). The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 88:2375-2384.
  • Hochhaus A; Reiter A; Skladny H; Melo JV; Sick C; Berger U; Guo JQ; Arlinghaus RB; et alHehlmann R; Goldman JM; Cross NC. (15 Sep 1996). A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood. 88:2236-2240.
  • Spencer A; Yan XH; Chase A; Goldman JM; Melo JV. (Sep 1996). BCR-ABL-positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions. Br J Haematol. 94:654-658.
  • Melo JV. (1 Aug 1996). Parental reciprocation bias in t(9;22) vs genomic imprinting - Reply. LEUKEMIA. 10:1403-1403. Author weblink.
  • Al-Jehani F; Hochhaus A; Spencer A; Goldman JM; Melo JV. (Jul 1996). Expression of the LH2 gene in chronic myeloid leukaemia cells. Leukemia. 10:1122-1126.
  • Melo JV; Yan XH; Diamond J; Lin F; Cross NC; Goldman JM. (Jul 1996). Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results. Leukemia. 10:1217-1221.
  • van Rhee F; Hochhaus A; Lin F; Melo JV; Goldman JM; Cross NC. (15 Jun 1996). p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood. 87:5213-5217.
  • Melo JV. (May 1996). The molecular biology of chronic myeloid leukaemia. Leukemia. 10:751-756.
  • Melo JV; Hochhaus A; Yan XH; Goldman JM. (Mar 1996). Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. Br J Haematol. 92:684-686.
  • MELO JV; GOLDMAN JM. (1 Aug 1995). ARE ABL AND BCR IMPRINTED - REPLY. LEUKEMIA. 9:1407-1408. Author weblink.
  • Melo JV; Goldman JM. (Aug 1995). Reply to Haas: Are ABL and BCR imprinted? (Leukemia 1995; 9: 740-743). Leukemia. 9:1407-1408.
  • Diamond J; Goldman JM; Melo JV. (15 Apr 1995). BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia. Blood. 85:2171-2175.
  • Melo JV; Yan XH; Diamond J; Goldman JM. (Apr 1995). Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia. Leukemia. 9:734-739.
  • O'Brien SG; Kirkland MA; Melo JV; Rao MH; Davidson RJ; McDonald C; Goldman JM. (Dec 1994). Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia. 8:2156-2162.
  • Melo JV; Kent NS; Yan XH; Goldman JM. (1 Dec 1994). Controls for reverse transcriptase-polymerase chain reaction amplification of BCR-ABL transcripts. Blood. 84:3984-3986.
  • Melo JV; Yan XH; Diamond J; Goldman JM. (Dec 1994). Lack of imprinting of the ABL gene. Nat Genet. 8:318-319. DOI.
  • MELO JV; YAN XH; DIAMOND J; GOLDMAN JM. (15 Nov 1994). BALANCED PARENTAL CONTRIBUTION TO THE ORIGIN OF THE DISRUPTED ABL GENE AND TO ABL EXPRESSION IN CHRONIC MYELOID-LEUKEMIA. BLOOD. 84:A513-A513. Author weblink.
  • Cross NC; Melo JV; Feng L; Goldman JM. (Jan 1994). An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 8:186-189.
  • Melo JV; Myint H; Galton DA; Goldman JM. (Jan 1994). P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?. Leukemia. 8:208-211.
  • MELO JV; MYINT H; GALTON DAG; GOLDMAN JM. (15 Nov 1993). P190(BCR-ABL) CHRONIC MYELOID-LEUKEMIA (CML) - THE MISSING LINK WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML). BLOOD. 82:A554-A554. Author weblink.
  • Melo JV; Gordon DE; Tuszynski A; Dhut S; Young BD; Goldman JM. (15 May 1993). Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia. Blood. 81:2488-2491.
  • Melo JV; Gordon DE; Cross NC; Goldman JM. (1 Jan 1993). The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood. 81:158-165.
  • Marti GE; Zenger V; Brown M; Marti DM; Melo JV; Crescenzi M; Dadey B; Han T; et alBertin P; Caporaso NE. (Aug 1992). Antigenic expression of B-cell chronic lymphocytic leukemic cell lines. Leuk Lymphoma. 7:497-504. DOI.
  • Melo JV; Goldman JM. (Aug 1992). Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia. Leukemia. 6:786-790.
  • Zola H; Melo JV; Zowtyj HN; Nikoloutsopoulos A; Skinner J. (Apr 1990). The leukocyte-common antigen (CD45) complex and B-lymphocyte activation. Hum Immunol. 27:368-377.
  • Melo JV; Foroni L; Brito-Babapulle V; Luzzatto L; Catovsky D. (Jul 1988). The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement. Clin Exp Immunol. 73:23-28.
  • MELO JV; HEGDE U; PARREIRA A; THOMPSON I; LAMPERT IA; CATOVSKY D. (1 Jun 1987). SPLENIC B-CELL LYMPHOMA WITH CIRCULATING VILLOUS LYMPHOCYTES - DIFFERENTIAL-DIAGNOSIS OF B-CELL LEUKEMIAS WITH LARGE SPLEENS. JOURNAL OF CLINICAL PATHOLOGY. 40:642-651. Author weblink DOI.
  • MELO JV; ROBINSON DSF; GREGORY C; CATOVSKY D. (1 Apr 1987). SPLENIC B-CELL LYMPHOMA WITH VILLOUS LYMPHOCYTES IN THE PERIPHERAL-BLOOD - A DISORDER DISTINCT FROM HAIRY-CELL LEUKEMIA. LEUKEMIA. 1:294-298. Author weblink.
  • THNG KH; GAREWAL G; KEARNEY L; RASSOOL F; MELO JV; WHITE H; CATOVSKY D; FORONI L; et alLUZZATTO L; GOLDMAN JM. (15 Jan 1987). ESTABLISHMENT AND CHARACTERIZATION OF 3 NEW MALIGNANT LYMPHOID-CELL LINES. INTERNATIONAL JOURNAL OF CANCER. 39:89-93. Author weblink DOI.
  • MELO JV; CATOVSKY D; GALTON DAG. (1 Jan 1987). CHRONIC LYMPHOCYTIC-LEUKEMIA AND PROLYMPHOCYTIC LEUKEMIA - A CLINICOPATHOLOGICAL REAPPRAISAL. BLOOD CELLS. 12:339-353. Author weblink.
  • GALLHOFER G; MELO JV; SPENCER J; CATOVSKY D. (1 Jan 1987). SPLENECTOMY IN ADVANCED CHRONIC LYMPHOCYTIC-LEUKEMIA. ACTA HAEMATOLOGICA. 77:78-82. Author weblink.
  • MELO JV; CATOVSKY D; GREGORY WM; GALTON DAG. (1 Jan 1987). THE RELATIONSHIP BETWEEN CHRONIC LYMPHOCYTIC-LEUKEMIA AND PROLYMPHOCYTIC LEUKEMIA .4. ANALYSIS OF SURVIVAL AND PROGNOSTIC FEATURES. BRITISH JOURNAL OF HAEMATOLOGY. 65:23-29. Author weblink DOI.
  • MELO JV; WARDLE J; CHETTY M; ENGLAND J; LEWIS SM; GALTON DAG; CATOVSKY D. (1 Nov 1986). THE RELATIONSHIP BETWEEN CHRONIC LYMPHOCYTIC-LEUKEMIA AND PROLYMPHOCYTIC LEUKEMIA .3. EVALUATION OF CELL-SIZE BY MORPHOLOGY AND VOLUME MEASUREMENTS. BRITISH JOURNAL OF HAEMATOLOGY. 64:469-478. Author weblink DOI.
  • MELO JV; BRITOBABAPULLE V; FORONI L; ROBINSON DSF; LUZZATTO L; CATOVSKY D. (15 Oct 1986). 2 NEW CELL-LINES FROM B-PROLYMPHOCYTIC LEUKEMIA - CHARACTERIZATION BY MORPHOLOGY, IMMUNOLOGICAL MARKERS, KARYOTYPE AND IG GENE REARRANGEMENT. INTERNATIONAL JOURNAL OF CANCER. 38:531-538. Author weblink DOI.
  • MELO JV; CATOVSKY D; GALTON DAG. (1 Sep 1986). THE RELATIONSHIP BETWEEN CHRONIC LYMPHOCYTIC-LEUKEMIA AND PROLYMPHOCYTIC LEUKEMIA .2. PATTERNS OF EVOLUTION OF PROLYMPHOCYTOID TRANSFORMATION. BRITISH JOURNAL OF HAEMATOLOGY. 64:77-86. Author weblink DOI.
  • MELO JV; CATOVSKY D; GALTON DAG. (1 Jun 1986). THE RELATIONSHIP BETWEEN CHRONIC LYMPHOCYTIC-LEUKEMIA AND PROLYMPHOCYTIC LEUKEMIA .1. CLINICAL AND LABORATORY FEATURES OF 300-PATIENTS AND CHARACTERIZATION OF AN INTERMEDIATE GROUP. BRITISH JOURNAL OF HAEMATOLOGY. 63:377-387. Author weblink.
  • PARREIRA A; ROBINSON DSF; MELO JV; AYLIFFE M; BALL S; HEGDE U; BAUGHAN A; FAIRHEAD S; et alTALAVERA JG; KATZMANN JA; CATOVSKY D. (1 Nov 1985). PRIMARY PLASMA-CELL LEUKEMIA - IMMUNOLOGICAL AND ULTRASTRUCTURAL STUDIES IN 6 CASES. SCANDINAVIAN JOURNAL OF HAEMATOLOGY. 35:570-578. Author weblink.
  • MELO JV; BRITOBABAPULLE V; ROBINSON DSF; CATOVSKY D. (1 Jan 1985). ESTABLISHMENT OF CONTINUOUS CELL-LINES FROM B-PROLYMPHOCYTIC LEUKEMIA (B-PLL). BRITISH JOURNAL OF HAEMATOLOGY. 61:573-574. Author weblink.
  • ROBINSON DSF; MELO JV; ANDREWS C; SCHEY SA; CATOVSKY D. (1 Jan 1985). INTRACYTOPLASMIC INCLUSIONS IN B-PROLYMPHOCYTIC LEUKEMIA - ULTRASTRUCTURAL, CYTOCHEMICAL, AND IMMUNOLOGICAL STUDIES. JOURNAL OF CLINICAL PATHOLOGY. 38:897-903. Author weblink DOI.
  • PARREIRA A; ROBINSON DSF; MELO JV; BALL S; FAIRHEAD S; HEGDE U; AYLIFF M; CATOVSKY D. (1 Jan 1985). PLASMA-CELL LEUKEMIA - IMMUNOLOGICAL AND ULTRASTRUCTURAL STUDIES IN 4 CASES. BRITISH JOURNAL OF HAEMATOLOGY. 61:550-550. Author weblink.
  • ROBINSON DSF; MELO JV; ANDREWS C; SCHEY SA; CATOVSKY D. (1 Jan 1985). UNUSUAL INTRACYTOPLASMIC INCLUSIONS IN A CASE OF B-PROLYMPHOCYTIC LEUKEMIA - AN ULTRASTRUCTURAL AND CYTOCHEMICAL ANALYSIS. BRITISH JOURNAL OF HAEMATOLOGY. 61:574-574.

Conferences

  • Batlle A; Papadopoulou V; Gomes AR; Willimott S; Melo JV; Naresh K; Lam EW; Wagner SD. MEMBRANE AND SOLUBLE CD40 LIGAND HAVE DIFFERENT EFFECTS ON BCL-6 EXPRESSION AND PRODUCE DIFFERENT PROTEIN/DNA COMPLEXES AT A SITE IN EXON 1 OF THE BCL-6 GENE. 14th Annual Meeting of the European-Hematology-Association, 4 Jun 2009 - 7 Jun 2009. 94:229-229. FERRATA STORTI FOUNDATION (1 Jun 2009). Author weblink.
  • Crawford L; Windrum P; Magill L; Melo JV; McCallum L; McMullin M; Ovaa H; Walker B; et alIrvine A. Ber-Abl Positive Cells Display Increased Proteasome Activity and Greater Sensitivity to Proteasome Inhibition. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:1095-1096. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
  • Esposito N; Colavita I; Izzo B; Quarantelli F; Sica RA; Buonomo T; Roberti V; Luciano L; et alDel Vecchio L; Peluso A; Melo J; Russo D; Martinelli G; Martinelli R; Ruoppolo M; Pane F. REDUCED LEVELS OF SHP1 PROVIDES AN ADDITIVE SURVIVAL ADVANTAGE TO THE PH+ CELLS OF CML PATIENTS AND MAY ACCOUNT FOR RESISTANCE TO IMA TREATMENT. 10th Congress of the Italian-Society-of-Experimental-Hematology, 24 Sep 2008 - 26 Sep 2008. 93:S20-S20. FERRATA STORTI FOUNDATION (1 Sep 2008). Author weblink.
  • Mohty M; Young ASM; Szydlo RM; Apperley JF; Goldman JM; Melo JV. Association between the polycomb group BMI-1 gene expression and outcome in chronic myeloid leukaemia patients receiving allogeneic stem cell transplantation. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S53-S54. NATURE PUBLISHING GROUP (1 Mar 2008). Author weblink.
  • Esposito N; Quarantelli F; Izzo B; Casadei GM; Luciano L; Saglio G; Melo JV; Kalebic T; et alMartinelli G; Pane F. Down-modulation of shp1 and hsp70 provides a survival advantage to the ph plus cells of CML patients additive to that related to the oncogenic BCR/ABL protein and may account for resistance to Ima treatment. 49th Annual Meeting of the American-Society-of-Hematology. 110:307A-307A. (16 Nov 2007).
  • Strathdee GR; Holyoake TL; Sim A; Parker A; Oscier DG; Melo JV; Meyer S; Eden T; et alDickinson AM; Mountford J; Jorgensen HG; Soutar R; Brown R. HOX genes - Candidate tumor suppressor genes in adult, and childhood leukemia. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:777A-777A. AMER SOC HEMATOLOGY (16 Nov 2007). Author weblink.
  • Hiwase DK; White DL; Saunders VA; Dang P; Venables A; Eadie L; Zrim S; To LB; et alMelo JV; Hughes TP. In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:575A-576A. AMER SOC HEMATOLOGY (16 Nov 2007). Author weblink.
  • Simoes MS; Score J; Cross NCP; Apperley JF; Melo JV. How cured are CML patients in complete molecular remission (CMR) after stem cell transplantation or imatinib?. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:306A-306A. AMER SOC HEMATOLOGY (16 Nov 2007). Author weblink.
  • Mohty M; Yong ASM; Szydlo RM; Apperley JF; Goldman JM; Melo JV. Association between the polycomb group (PcG) BMI-1 gene expression and outcome in chronic myeloid leukemia (CML) patients receiving allogeneic stem cell transplantation (allo-SCT). 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:143A-143A. AMER SOC HEMATOLOGY (16 Nov 2007). Author weblink.
  • Esposito N; Izzo B; Quarantelli F; Colavita I; Buonomo T; Roberti V; Soverini S; Melo JV; et alMartinelli G; Martinelli R; Ruoppolo M; Rotoli B; Pane F. Multiple molecular mechanism may account for resistance to imatinib in resistant cell lines. 41st Congress of the Italian-Society-of-Hematology. 92:44-44. (Oct 2007).
  • Elliston DJ; Miller-Reynolds AR; Melo JV; Apperley JF. The use of suicide genes in the treatment of chronic myeloid leukemia. 44th Annual Meeting of the American-Society-of-Hematology. 100:486B-486B. (16 Nov 2002).
  • Sweeney CL; Frandsen JL; Verfaillie CM; Melo JV; McIvor RS. Effect of STI571 withdrawal and p210 over-expression on tumorigenicity and cell viability of STI571-resistant chronic myeloid leukemia. 6th Annual Meeting of the American-Society-of-Gene-Therapy. 7:S295-S296. (May 2003).
  • Yoshida C; Yoshida F; Vieira SA; Makri M; Muto A; Igarashi K; Goldman JM; Melo JV. The transcription factor Bach2 is phosphorylated via PI-3 kinase by Bcr-Abl. 45th Annual Meeting of the American-Society-of-Hematology. 102:578A-579A. (16 Nov 2003).
  • Whetton AD; Burthem J; Griffiths SD; Blinco D; Melo JV; Lucas G; Holyoake TL. Proteomic assessment of imatinib effects on CD34 enriched cells from chronic myeloid leukemia patients using difference in gel electrophoresis (DIGE). 45th Annual Meeting of the American-Society-of-Hematology. 102:420A-420A. (16 Nov 2003).
  • Yong ASM; Tipping AJ; Goldman JM; Melo JV. The gene expression profile of CML CD34+ cells can predict the duration of chronic phase. 45th Annual Meeting of the American-Society-of-Hematology. 102:419A-419A. (16 Nov 2003).
  • Schultheis B; Fidanis E; Mahon FX; Apperley JF; Goldman JM; Melo JV. Development of a test to predict resistance to imatinib mesylate in the treatment of chronic myeloid leukemia. 45th Annual Meeting of the American-Society-of-Hematology. 102:71A-72A. (16 Nov 2003).
  • Chuah C; Tipping AJ; Goldman JM; Melo JV. Zoledronate is active against imatinib mesylate-resistant chronic myeloid leukemia cell lines and synergistic/additive when combined with imatinib mesylate. 45th Annual Meeting of the American-Society-of-Hematology. 102:19A-19A. (16 Nov 2003).
  • Koenig H; Moseson EM; Lorentz C; Paschka P; Melo JV; Hehlmann R; Hochhaus A; La Rosee P. Glutathione-depletion potently enhances the cytotoxic activity of arsenic trioxide in imatinib sensitive and resistant Bcr-Abl positive cell lines. 46th Annual Meeting of the American-Society-of-Hematology. 104:577A-577A. (16 Nov 2004).
  • Mijus J; Melo JV; Boros L; Anderson N; Talpaz M; Leibfritz D; Eckhardt GS; Serkova N. Metabolic profile of imatinib resistance in CML cells. 46th Annual Meeting of the American-Society-of-Hematology. 104:547A-547A. (16 Nov 2004).
  • Pasquet JM; Pocaly M; Lagarde V; Turcq A; Reiffers J; Melo JV; Mahon FX. The Proteome analysis of an imatinib-resistant cell line identifies changes in molecular chaperones such as heat shock proteins (Hsp): A possible new mechanism of imatinib resistance. 46th Annual Meeting of the American-Society-of-Hematology. 104:547A-547A. (16 Nov 2004).
  • Strathdee G; Holyoake TL; Sim A; Melo JV; Soutar R; Parker A; Oscier DG; Brown R. HoxA cluster genes are frequently targeted by DNA methylation in CML and other types of human leukaemia. 34th Annual Meeting of the International-Society-for-Experimental-Hematology. 33:50-50. (Jul 2005).
  • Makri M; Yoshida C; Muto A; Igarashi K; Melo JV. Transcriptional regulation of the Bach2 B-cell differentiation and apoptotic factor by the Bcr-Abl oncoprotein. 47th Annual Meeting of the American-Society-of-Hematology. 106:838A-838A. (16 Nov 2005).
  • Yong ASM; Szydlo RM; Goldman JM; Apperley JF; Melo JV. Molecular profiling of CD34+cells from diagnosis in CML patients identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival. 47th Annual Meeting of the American-Society-of-Hematology. 106:562A-562A. (16 Nov 2005).
  • La Rosee P; Jia TP; Demehri S; de Vries P; Bonham L; Melo JV; Singer JW; Druker BJ; et alDeminger MW. Selective inhibition of lysophosphatidic acid acyltransferase-beta by CT32228 inhibits MAPK and enhances the antileukemic activity of imatinib in BCR-ABL expressing cell lines resistant to imatinib. 47th Annual Meeting of the American-Society-of-Hematology. 106:438A-438A. (16 Nov 2005).
  • Serkova NJ; Kominsky DJ; Brown JL; Miljus J; Boros LG; Eckhardt GS; Melo JV. Abnormalities in glucose uptake and metabolism in imatinib-resistant Bcr-Abl positive cells. 48th Annual Meeting of the American-Society-of-Hematology. 108:662A-662A. (16 Nov 2006).
  • Copland M; Richmond L; Hamilton A; Allan EK; Melo JV; Holyoake TL. BMS-214662 eliminates CML stem cells and is active against blast crisis CML and cells expressing BCR-ABL kinase mutations. 48th Annual Meeting of the American-Society-of-Hematology. 108:222A-222A. (16 Nov 2006).
  • Strathdee G; Holyoake TL; Sim A; Parker A; Oscier DG; Melo JV; Meyer S; Eden T; et alDickinson AM; Soutar R; Brown R. HOX genes are a major target for epigenetic mis-regulation in adult and childhood leukaemia. 47th Annual Scientific Meeting of the British-Society-for-Haematology. 137:81-81. (Apr 2007).
  • Pane F; Esposito N; Izzo B; Quarantelli F; Colavita I; Buonomo T; Roberti V; Soverini S; et alMelo JV; Martinelli G; Martinelli R; Ruoppolo M; Pane F. Multiple molecular mechanism may account for resistanceto imatinib in resistant cell lines. 12th Congress of the European-Hematology-Association. 92:418-418. (Jun 2007).
  • Brazma D; Grace C; Virgili A; Howard J; Chanalaris A; Melo JV; Apperley JF; Nacheva EP. When is a double Philadelphia not a double Philadelphia. 12th Congress of the European-Hematology-Association. 92:202-202. (Jun 2007).
  • Markova B; Breitenbuecher F; Melo JV; Duyster J; Huber C; Fischer T. Novel pathway in BCR-ABL signal transduction involves Akt-independent activation of PLC-gamma/mTOR/P70-S6 kinase. 12th Congress of the European-Hematology-Association, 7 Jun 2007 - 10 Jun 2007. 92:338-338. FERRATA STORTI FOUNDATION (1 Jun 2007). Author weblink.
  • Mohty M; Yong ASM; Szydlo RM; Apperley JF; Melo JV. The polycomb group BMI-1 gene is a molecular marker for predicting prognosis of chronic myeloid leukaemia. 12th Congress of the European-Hematology-Association, 7 Jun 2007 - 10 Jun 2007. 92:196-197. FERRATA STORTI FOUNDATION (1 Jun 2007). Author weblink.
  • Khorashad JS; Lipton JH; Marin D; Milojkovic D; Cross NCP; Dibb N; Melo JV; Kamel-Reid S; et alGoldman JM; Apperley JF; Kaeda JS. Abnormally small BCR-ABL transcripts in CML patients before and during imatinib treatment. 48th Annual Meeting of the American-Society-of-Hematology, 9 Dec 2006 - 12 Dec 2006. 108:611A-611A. AMER SOC HEMATOLOGY (16 Nov 2006). Author weblink.
  • Sanchez VJ; Aceves CI; Gomez JC; Manso F; Romero JR; Melo JV; Sanchez-Prieto R. Activation of the P38 MAPK pathway mediates resistance to Ara-C y Bcr/Abl positive cells. 47th Annual Meeting of the American-Society-of-Hematology, 10 Dec 2005 - 13 Dec 2005. 106:439A-439A. AMER SOC HEMATOLOGY (16 Nov 2005). Author weblink.
  • Radujkovic A; Schad M; Topaly J; Laufs S; Jauch A; Schultheis B; Melo JV; Ho AD; et alFruehauf S; Zeller WJ. Synergism between 17-AAG and imatinib in imatinib-resistant CML cells: Inhibition of P-glycoprotein by 17-AAG as a new mechanism of increasing imatinib activity. 46th Annual Meeting of the American-Society-of-Hematology, 4 Dec 2004 - 7 Dec 2004. 104:576A-576A. AMER SOC HEMATOLOGY (16 Nov 2004). Author weblink.
  • Barnes DJ; Goldman JM; Melo JV. BCR-ABL expression levels determine the rate of development of resistance to imatinib mesylate (Gleevec). 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:415A-415A. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
  • La Rosee P; Johnson K; Corbin AS; Stoffregen EP; Melo JV; Hochhaus A; Deininger MW; Druker BJ. Effective combination treatment with imatinib requires residual Bcr-Abl-inhibition in imatinib-resistant cell lines. 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:19A-20A. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
  • Tipping AJ; Baluch S; Mahon FX; Veach DR; Bornmann WG; Clarkson BD; Goldman JM; Melo JV. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:858A-858A. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
  • Pattacini L; Barnes DJ; Weiss U; Schultheis B; Goldman JM; Melo JV. Transcription of the human cell cycle checkpoint kinase Chk1 is inhibited by the Bcr-Abl oneoprotein. 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:228A-229A. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
  • Schad M; Topaly J; Laufs S; Zeller WJ; Melo JV; Fruehauf S. Combination of Hsp90 blocker 17-AAG and imatinib shows synergistic activity in imatinib-resistant chronic myelogenous leukemia cells. 44th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2002 - 10 Dec 2002. 100:319A-319A. AMER SOC HEMATOLOGY (16 Nov 2002). Author weblink.
  • Lerma E; Tao W; Nguyen V; Tipping A; Melo JV; Austin D; Deisseroth AB. Development of novel drugs which suppress STI571 resistant cell lines and synergize with imatinib mesylate. 44th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2002 - 10 Dec 2002. 100:318A-318A. AMER SOC HEMATOLOGY (16 Nov 2002). Author weblink.
  • Nijmeijer BA; van Schie MLJ; Walker EJ; Willemze R; Melo JV; Falkenburg JHF. In vivo kinetics of imatinib mesylate treatment of chronic myeloid leukemia blast crisis using a NOD/SCID mouse model. 44th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2002 - 10 Dec 2002. 100:561A-561A. AMER SOC HEMATOLOGY (16 Nov 2002). Author weblink.
  • Melo JV. The molecular biology of chronic myeloid leukaemia. 9th Symposium on Molecular Biology of Hematopoiesis and Treatment of Leukemias and Lymphomas, 23 Jun 1995 - 27 Jun 1995. 10:S4-S9. STOCKTON PRESS (1 Jun 1996). Author weblink.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook